AUTOLOGUS CELL THERAPY
Opexa 'eliminates major liabilities' by selling Texas facility to KBI
CDMO KBI Biopharma, Inc. has acquired the lease and assets of Opexa Therapeutics’ facility in Texas after the firm’s lead MS candidate failed Ph IIb.
Archives for February 6, 2017
Global logistics strategies for cell and gene therapies
Paid for and content provided by World Courier
Personalized medicines require a personalized supply chain. Find out more from World Courier.
Trump's travel restrictions will hurt cell therapy sector says ISCT
If reinstated, Donald Trump’s order restricting travel to the US would hurt the cell therapy sector according to the International Society for Cellular Therapy (ISCT).